Structural comparison of androstenediol recognition by the human estrogen receptor ligand binding domains
Molecular and Cellular Endocrinology · 2025
DOI: 10.1016/j.mce.2025.112588 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Molecular and Cellular Endocrinology, 2025. Verfasst von Jordan L Pederick und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Photonics and Advanced Sensing (IPAS), School of Biological Sciences, The University of Adelaide, Adelaide, South Australia, 5005, Aust…. Hauptthemen laut MEDLINE: Androstenediol, Estrogen Receptor beta, Estrogen Receptor alpha. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian Cancer Research Foundation, Australian Research Council.
Abstract (Originalsprache)
Estrogen receptors α (ERα) and β (ERβ) are ligand-regulated transcription factors that control important biological processes in humans. The endogenous steroid androstenediol possesses estrogenic activity, despite being a precursor of the primary androgen, testosterone. While androstenediol is an agonist of both ERs, it is ∼ 3-fold selective for ERβ. Additionally, it has been reported that androstenediol can repress proinflammatory responses of the central nervous system (CNS) in an ERβ-dependent manner, but the primary estrogen, estradiol (E2), cannot. As no structural characterization of the interaction between ERα or ERβ with androstenediol has been reported, the basis of ERβ selectivity, and whether this is responsible for the anti-inflammatory effects of androstenediol, remains unclear. To address these gaps in knowledge we determined crystal structures of the human ER LBDs (hERα and hERβ) complexed with androstenediol and coactivator-derived peptide. This revealed that androstenediol stabilizes the active conformation of both receptors in the same manner as E2. The binding mode of androstenediol between the hERα and hERβ LBDs is extremely similar, suggesting that subtle differences in the van der Waals interactions mediated by non-conserved residues of the ligand binding pocket confer selectivity toward hERβ. Finally, in both receptors the coactivator-derived peptide occupied the activation function 2 (AF2) surface, as observed for previous agonist-bound hER structures. Therefore, as androstenediol does not induce any distinct structural changes within the hERβ LBD compared to E2, this suggests that the hERβ-dependent anti-inflammatory effects of androstenediol on the CNS are mediated by other factors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Photonics and Advanced Sensing (IPAS), School of Biological Sciences, The University of Adelaide, Adelaide, South Australia, 5005, Australia.
- Institute for Photonics and Advanced Sensing (IPAS), School of Biological Sciences, The University of Adelaide, Adelaide, South Australia, 5005, Australia. Electronic address: john.bruning@adelaide.edu.au.
Förderung
- Australian Cancer Research Foundation
- Australian Research Council
Zitieren
APA
Pederick, J. L., & Bruning, J. B. (2025). Structural comparison of androstenediol recognition by the human estrogen receptor ligand binding domains. Molecular and Cellular Endocrinology. https://doi.org/10.1016/j.mce.2025.112588
Vancouver
Pederick JL, Bruning JB. Structural comparison of androstenediol recognition by the human estrogen receptor ligand binding domains. Molecular and Cellular Endocrinology. 2025. doi:10.1016/j.mce.2025.112588
BibTeX
@article{Pederick2025,
author = {Pederick, Jordan L and Bruning, John B},
title = {Structural comparison of androstenediol recognition by the human estrogen receptor ligand binding domains},
journal = {Molecular and Cellular Endocrinology},
year = {2025},
doi = {10.1016/j.mce.2025.112588}
}
EUVIMED